Saturday 17 October 2026
Export ZBIO’s income statement to Excel — free account
Zenas BioPharma, Inc.
ZBIO Healthcare Biotechnology
Zenas BioPharma, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $10.0 million, up 100.0% from fiscal 2024. In the quarter to June 2026, EPS fell 41.6% and free cash flow fell 37.1%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
24.67
0.73
−2.87%
Follow ZBIO
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | — | — | — |
+8 more quarters Free account |
P/S ratio |
0.00 | — | — | — | |
P/FCF ratio |
0.00 | — | — | — | |
P/Operating CF |
(27.99) | — | — | — | |
P/B ratio |
6.48 | — | — | — | |
Price to Tangible BV |
6.48 | — | — | — | |
EV/Sales |
0.00 | — | — | — | |
EV/EBITDA |
0.00 | — | — | — | |
EV/Operating CF |
(5.96) | — | — | — | |
EV/FCF |
(5.96) | — | — | — | |
Quick Ratio |
9.77 | 11.73 | 5.48 | 5.55 | |
Current Ratio |
9.93 | 11.94 | 5.61 | 5.66 | |
Net Debt/EBITDA |
2.36 | 4.74 | 1.11 | 4.14 | |
Debt/Assets |
55.40% | 46.89% | 20.50% | 22.67% | |
Debt/Equity |
1.57 | 1.04 | 0.32 | 0.37 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.51 | 0.93 | 0.22 | 0.80 | |
Capex/Depreciation |
0.00 | (0.33) | 0.00 | 0.00 | |
Interest Coverage |
(10.45) | (11.66) | — | — | |
Research and Development Expense of Revenue |
6,291.30% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
1,574.60% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
861.90% | 0.00% | 0.00% | 0.00% | |
Graham Net Nets |
0.12 | — | — | — | |
Graham Number |
0.00 | — | — | — | |
Earnings Yield |
(35.42%) | — | — | — | |
Free Cash Flow Yield |
(14.11%) | — | — | — | |
Revenue per Share |
0.02 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.91) | (1.35) | (1.17) | (0.98) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.91) | (1.35) | (1.17) | (0.98) | |
Cash per Share |
10.19 | 12.89 | 7.67 | 6.90 | |
Shareholders Equity per Share |
3.92 | 6.04 | 5.41 | 4.66 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
3.92 | 6.04 | 5.41 | 4.66 | |
Free Cash Flow |
(57.24) | (75.20) | (52.41) | (41.12) | |
Working Capital |
587.98 | 669.00 | 288.52 | 244.22 | |
Capital Expenditures |
0.00 | 0.00 | 0.00 | 0.00 | |
Net Current Asset Value |
199.20 | 318.31 | 209.68 | 171.05 | |
EV/EBIT |
0.00 | — | — | — | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Operating Income |
0.00 | — | — | — | |
| Other line items | |||||
Average Payables |
7.76 | 14.48 | 12.12 | 10.76 | |
Average Assets |
497.39 | 540.72 | 376.80 | 362.73 | |
Average Common Equity |
243.36 | 310.07 | 277.30 | 277.93 |
Columns are period end dates